Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
Evofem Biosciences's gross margin for the twelve months ending Jun 30, 2026 was 75.5%. For fiscal 2025 it was 77.1%, against 80.2% the year before. The highest annual figure on record is 80.2% in fiscal 2024.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 77.1% | −3.1 |
| FY2024 | Dec 31, 2024 | 80.2% | +15.9 |
| FY2023 | Dec 31, 2023 | 64.3% | −9.5 |
| FY2022 | Dec 31, 2022 | 73.8% | +23.0 |
| FY2021 | Dec 31, 2021 | 50.8% | +55.7 |
| FY2020 | Dec 31, 2020 | -4.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 80.6% | −3.8 |
| Q1 FY2026 | Mar 31, 2026 | 54.4% | −2.4 |
| Q4 FY2025 | Dec 31, 2025 | 72.9% | −5.8 |
| Q3 FY2025 | Sep 30, 2025 | 81.7% | +1.1 |
| Q2 FY2025 | Jun 30, 2025 | 84.4% | +2.8 |
| Q1 FY2025 | Mar 31, 2025 | 56.8% | −24.2 |
| Q4 FY2024 | Dec 31, 2024 | 78.7% | +72.0 |
| Q3 FY2024 | Sep 30, 2024 | 80.7% | +4.4 |
| Q2 FY2024 | Jun 30, 2024 | 81.5% | +193.7 |
| Q1 FY2024 | Mar 31, 2024 | 81.0% | +7.4 |
| Q2 FY2023 | Jun 30, 2023 | 6.7% | −72.0 |
| Q1 FY2023 | Mar 31, 2023 | 76.3% | +1.4 |
| Q4 FY2022 | Dec 31, 2022 | -112.2% | −163.0 |
| Q3 FY2022 | Sep 30, 2022 | 73.6% | +29.4 |
| Q2 FY2022 | Jun 30, 2022 | 78.7% | +23.9 |
| Q1 FY2022 | Mar 31, 2022 | 74.9% | +20.7 |
| Q4 FY2021 | Dec 31, 2021 | 50.8% | +40.7 |
| Q3 FY2021 | Sep 30, 2021 | 44.2% | +58.2 |
| Q2 FY2021 | Jun 30, 2021 | 54.8% | – |
| Q1 FY2021 | Mar 31, 2021 | 54.2% | – |
| Q4 FY2020 | Dec 31, 2020 | 10.1% | – |
| Q3 FY2020 | Sep 30, 2020 | -14.0% | – |
See a number that looks wrong?